Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-Label, Phase Ib Study of Sintilimab and Linperlisib Combination Treatment in Patients with Relapsed or Refractory Extranodal Natural Killer/T Cell Lymphoma (NKTCL)

NCT06793956 is registered in ClinicalTrials.gov with Sun Yat-sen University as lead sponsor.

NCT NCT06793956
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06793956 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-Label, Phase Ib Study of Sintilimab and Linperlisib Combination Treatment in Patients with Relapsed or Refractory Extranodal Natural Killer/T Cell Lymphoma (NKTCL)
Lead sponsor
Sun Yat-sen University
Phase
Phase 1
Overall status
Recruiting
Start date
February 21, 2025
Completion date
January 31, 2030
Enrollment
12 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

extranodal natural killer/t cell lymphoma